Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Cost-effectiveness analysis at 2 years of surgical treatment of benign prostatic...
Journal Information
Vol. 38. Issue 4.
Pages 238-243 (May 2014)
Share
Share
Download PDF
More article options
ePub
Visits
476
Vol. 38. Issue 4.
Pages 238-243 (May 2014)
Original article
DOI: 10.1016/j.acuroe.2014.02.007
Cost-effectiveness analysis at 2 years of surgical treatment of benign prostatic hyperplasia by photoselective vaporization of the prostate with GreenLight-PhotoVaporization 120W versus transurethral resection of the prostate
Análisis coste efectividad a 2 años del tratamiento quirúrgico de la hiperplasia benigna de próstata mediante vaporización fotoselectiva de la próstata con GreenLight-PhotoVaporization 120W versus resección transuretral de la próstata
Visits
...
J.M. Benejam-Guala, A. Sanz-Grandab,
Corresponding author
a.sanzgranda@terra.com

Corresponding author.
, R. García-Miralles Grávalosa, A. Severa-Ruíz de Velascoa, J. Pons-Vivera
a Servicio de Urología, Hospital de Manacor, Manacor, Islas Baleares, Spain
b Proyectos de Farmacoeconomía, Navacerrada, Madrid, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (4)
Table 1. Characteristics of the patient sample.
Table 2. Use of healthcare resources.
Table 3. Unit prices of the healthcare resources used.
Table 4. Total cost and breakdown by items of surgeries performed.
Show moreShow less
Abstract
Introduction

Transurethral resection of the prostate is the gold standard of surgical treatment of lower urinary tract symptoms associated to benign prostate hyperplasia. The new GreenLight PhotoVaporization has been shown to be an alternative that is as effective for this condition as the transurethral resection of the prostate.

Objectives

To compare the efficiency of GreenLight PhotoVaporization 120W versus transurethral resection of the prostate in the treatment of benign prostate hyperplasia (BPH) in a 2-year time horizon from the Spanish health service perspective.

Methods

A cost utility analysis was performed retrospectively with the data from 98 patients treated sequentially with transurethral resection of the prostate (n: 50) and GreenLight PhotoVaporization 120W (n: 48). A Markov model was designed to estimate the cost (2012€) and results (quality adjusted life years) in a 2-year time horizon.

Results

The total cost associated to GreenLight PhotoVaporization 120W treatment was less (3377€; 95% CI: 3228; 3537) than that of the transurethral resection of the prostate (3770€; 95% CI: 3579; 3945). The determining factor of the cost was the surgical phase (difference: −450€; 95% CI: −625; −158) because admission to hospital after surgery was not necessary with the GreenLight-PhotoVaporization.

Conclusions

Surgical treatment of BPH patients with GreenLight-PhotoVaporization 120W is more efficient than transurethral resection of the prostate in the surgical treatment of benign prostate hyperplasia as it has similar effectiveness and lower cost (−393€; 95% CI: −625; −158).

Keywords:
GreenLight-PhotoVaporization
Transurethral resection of the prostate
Cost-effectiveness
Benign prostate hyperplasia
Resumen
Introducción

El gold standard del tratamiento quirúrgico de la sintomatología del tracto urinario inferior asociado a la hiperplasia benigna de próstata ha sido la resección transuretral de la próstata; GreenLight-PhotoVaporization ha demostrado ser una alternativa quirúrgica tan efectiva como aquella.

Objetivo

Analizar la eficiencia comparada, en un horizonte temporal de 2 años, de GreenLight-PhotoVaporization 120W respecto de la resección transuretral de la próstata en el tratamiento quirúrgico de la hiperplasia benigna de próstata desde la perspectiva del sistema de salud de España.

Métodos

Se realizó un análisis de coste utilidad a partir de los resultados obtenidos retrospectivamente en 98 pacientes intervenidos secuencialmente mediante resección transuretral de la próstata (n: 50) y GreenLight-PhotoVaporization 120W (n: 48). Se utilizó un modelo de Markov para estimar el coste (€, 2012) y los resultados (años de vida ajustados a calidad) tras un seguimiento de 2 años.

Resultados

El coste total asociado al tratamiento con GreenLight-PhotoVaporization 120W fue inferior (3.377€; IC 95%: 3.228; 3.537) al de la resección transuretral de la próstata (3.770€; IC 95%: 3.579; 3.945). El determinante del coste se presenta en la fase quirúrgica (diferencia: −450€; IC 95%: −625; −158) debido a que GreenLight-PhotoVaporization 120W no precisaba ingresar al paciente tras la cirugía.

Conclusiones

El tratamiento quirúrgico de los pacientes con HBP mediante GreenLight-PhotoVaporization 120W muestra mayor eficiencia respecto de la resección transuretral de la próstata al observarse una efectividad similar y un coste inferior (−393€; IC 95%: −625; −158).

Palabras clave:
GreenLight-PhotoVaporization
Resección transuretral de la próstata
Coste-efectividad
Hiperplasia benigna de próstata

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos